BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has amended the terms of its ...

In the field of cancer immunotherapy, unconventional T cells (UCTs) and Chimeric Antigen Receptor (CAR) T cells have emerged as promising areas of research ...

Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 ...

Myrio's PHOX2B PC-CAR T therapy gains FDA approval for human trials, promising innovative treatment for patients with ...

Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of a new ...

Myrio Therapeutics Pty Ltd. is set to advance lead product PHOX2B PC-CAR T (PHOX2B peptide-centric chimeric antigen receptor autologous T cells) into clinical trials for relapsed neuroblastoma ...

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to ...

The U.S. Food and Drug Administration (FDA) has approved Myrio Therapeutics' Investigational New Drug (IND) application for its lead product, PHOX2B PC-CAR T, paving the way for human trials in ...

Enterome has secured $19m in new private funding to progress its EO2463 OncoMimics immunotherapy, targeting iNHL.

New U.S. investor The Institute for Follicular Lymphoma Innovation (IFLI), a global non-profit foundation dedicated to advancing research and treatment for follicular lymphoma, invested $9 million in ...

A study in Chemistry A European Journal reveals that reduced MUC1 antigen density on gold nanoparticles still elicits potent ...